|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> The typical deposition of <sup>18</sup>F-AV1451 tau PET imaging in AD brain was found in amygdala, entorhinal cortex, fusiform and parahippocampus, and these regions were strongly associated with cognitive impairment and CSF biomarkers.
|
31156534 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
3446 individuals (1154 AD cases and 2292 controls) were included in the analyses of AD risk, 1400 individuals (cognitively normal = 747, AD = 653) in the CSF biomarker analyses, and 861 individuals in the analyses of cognitive decline.
|
30792413 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF biomarkers like Amyloid beta 42, total tau and phosphorylated tau levels can be easily evaluated in individuals suffering from cognitive decline, to diagnose or exclude AD type dementia, since early stages.
|
28124618 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF flux is involved in the pathophysiology of neurodegenerative diseases and cognitive impairment after traumatic brain injury, all hallmarked by the accumulation of cellular metabolic waste.
|
28137972 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF A<i>β</i>, <i>α</i>-synuclein, and neurogranin concentrations are related to cortical metabolism and cognitive decline.
|
29046879 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, we tried to identify a cerebrospinal fluid (CSF) biomarker correlated with the degree and rate of cognitive decline in progressive MS patients.
|
31802039 |
2020 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients completed neuropsychological tests, core CSF AD biomarkers assessment (Aβ<sub>1-42</sub>, total tau, and phosphorylated tau), and follow-up for a mean of 3 years to verify cognitive decline.
|
30317034 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of 4 subgroups (Cognitive impairment ± and Biomarkers ±) showed significant associations of dementia and CSF biomarker concentrations to mortality after an AHF.
|
31508810 |
2020 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baseline FDG-PET and episodic memory predict conversion to AD, whereas p-tau(181p)/Abeta(1-42) and, marginally, FDG-PET predict longitudinal cognitive decline.
|
20592257 |
2010 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Concentrations of CSF biomarkers, additionally to severity of the cognitive impairment, significantly contribute in predicting specific personality changes.
|
28213293 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Delirium is a marker of brain vulnerability, associated with increasing age, pre-existing cognitive impairment and, recently, cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease.
|
30862889 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated CSF cortisol may also be associated with a more rapid cognitive decline in MCI due to AD.
|
30881301 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated baseline plasma NfL is a prognostic marker of cognitive decline and neuroimaging measures of neurodegeneration, and has similar effect sizes to baseline CSF NfL.
|
31182505 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert commentary: A large number of pilot studies have been reported but so far there is a lack of replicated findings and to date no CSF biomarker discovered in proteomic studies has reached the clinic to aid in the diagnostic work-up of patients with cognitive impairment.
|
28942688 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, in case of co-existence of cognitive impairment and depression in the elderly, we propose CSF AD biomarkers analysis to early differentiate LLD from AD and properly target the patient's therapeutic strategy and clinical follow-up.
|
29527163 |
2018 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In an asymptomatic at-risk cohort, elevated CSF Aβ (with or without elevated tau) was associated with greater rates of cognitive decline, with the specific pattern of decline varying across cognitive measures.
|
29523644 |
2018 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most use CSF biomarkers to diagnose atypical (84%) and early-onset cases of cognitive impairment (71%) and for the differential diagnosis of other dementias (69%).
|
28826189 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum and CSF levels of anti-Aβ autoantibodies and CSF biomarkers were evaluated in 68 patients with cognitive impairment, comprising 44 patients with AD, 19 patients with amnestic MCI and five patients with non-Alzheimer's dementia.
|
27330118 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subanalysis of the separate diagnostic groups demonstrated significant correlations between CSF biomarkers and generalized power and synchronization already in the subjective cognitive decline and mild cognitive impairment group.
|
29245058 |
2018 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Surgical goals for this patient included the following: 1) removal of potentially epileptogenic and dysfunctional tissue; 2) preservation of cranial nerves; 3) prevention of cognitive decline or iatrogenic deficit; 4) prevention of CSF leak; 5) reconstruction of skull base; 6) prevention of airway and swallowing compromise; and 7) cosmesis.
|
31628278 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taking advantage of repeated amyloid PET and CSF measures, this dynamic view offers new insight into the progression of Alzheimer's disease biomarkers and their relationships with cognitive decline.
|
31350262 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
The finding that amnestic MCI based on brief neuropsychological assessment is significantly associated with CSF biomarkers for cognitive decline and Alzheimer's disease is in accordance with longitudinal studies that find memory impairment; both in itself and especially in combination with other cognitive deficit to constitute a risk factor for subsequent cognitive decline and dementia.
|
30614807 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hypoperfusion pattern discriminated between patients with positive CSF AD biomarkers and those with other cognitive impairments with a sensitivity of 67% to 71% and a specificity of 63% to 65% and a greatest negative predictive value (NPV) of 90%.
|
29261520 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
The primary objective of this study was to assess the possible association between BMI and cerebrospinal fluid (CSF) biomarkers of AD pathology in subjects with normal cognition and cognitive impairment.
|
29054536 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relationship of contactin-2 with cognitive decline (Mini-Mental State Examination (MMSE)) and other CSF biomarkers reflecting AD pathology were analyzed.
|
29859129 |
2018 |